Tabuvan 1 Tablets / Film-coated

Tabuvan 1 Tablets / Film-coated is used for: Heart failure, Hypertension, Post myocardial infarction

Oral Hypertension Adult: Initially, 80 mg once daily, may be increased to 160 mg once daily if needed. Max: 320 mg once daily. Heart failure Adult: Initially, 40 mg bid, may be increased to 160 mg bid if tolerated. Post myocardial infarction Adult: Start as early as 12 hr after MI in stable patients at an initial dose of 20 mg bid, doubled at intervals over a few wk up to 160 mg bid if tolerated. Elderly: No dosage adjustment needed. Hepatic impairment: Mild to moderate: Max: 80 mg once daily. Severe: Contraindicated.

Oral Hypertension Child: As tab: >6 yr <35 kg: Initially, 40 mg once daily. Max: 80 mg once daily; 35-80 kg: Initially, 80 mg once daily. Max: 160 mg once daily; >80 kg: Initially, 80 mg once daily. Max: 320 mg once daily.

Renal impairment CrCl >30 mL/min: No dose adjustment necessary in adults CrCl <30 mL/min: Use with caution in adults; not studied in children

May be taken with or without food.

Hypersensitivity; severe hepatic impairment, cirrhosis or biliary obstruction; primary hyperaldosteronism. Pregnancy (2nd and 3rd trimesters) and lactation.

Patients w/ renal artery stenosis, heart failure, aortic or mitral stenosis, severe Na and/or volume depletion. Renal and mild to moderate hepatic impairment. Lactation. Monitoring Parameters Monitor BP, electrolytes, renal function. Monitor serum K levels every dose increment and periodically thereafter.

Pregnancy The drug can cause fetal harm when administered to a pregnant woman; use of drugs that act on renin-angiotensin system during second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents When pregnancy is detected, discontinue therapy as soon as possible Hypertension in pregnancy increases maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (eg, need for cesarean section, and post-partum hemorrhage) Hypertension increases fetal risk for intrauterine growth restriction and intrauterine death; pregnant women with hypertension should be carefully monitored and managed accordingly Fetal/neonatal adverse reactions Oligohydramnios in pregnant women who use drugs affecting the renin-angiotensin system in second and third trimesters of pregnancy can result in reduced fetal renal function leading to anuria and renal failure, fetal lung hypoplasia, skeletal deformations, including skull hypoplasia, hypotension and death Perform serial ultrasound examinations to assess the intra-amniotic environment; fetal testing may be appropriate, based on the week of gestation; oligohydramnios may not appear until after the fetus has sustained irreversible injury If oligohydramnios is observed, consider alternative drug treatment; closely observe neonates with histories of in utero exposure to the drug for hypotension, oliguria, and hyperkalemia; in neonates with a history of in utero exposure to the drug, if oliguria or hypotension occurs, support blood pressure and renal perfusion Exchange transfusions or dialysis may be required as a means of reversing hypotension and replacing renal function Lactation There is limited information regarding presence of the drug in human milk, effects on breastfed infant, or on milk production; the drug is present in rat milk Because of the potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment with this drug

May antagonise hypotensive effects and increase the risk of renal impairment w/ NSAIDs. Increased risk of hyperkalaemia w/ K-sparing diuretics, K supplements or K-containing salt substitutes. Potentially Fatal: Increased risk of hypotension, hyperkalemia and changes in renal function (including acute renal failure) when used w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).

Side effects of Valsartan : >10% Dizziness (17%; heart failure), Increased blood urea nitrogen (BUN; 17%) 1-10% Hyperkalemia (4-10%), Dizziness (2-8%; hypertension), Hypotension (1-7%; heart failure), Fatigue (3%), Viral infection (3%), Neutropenia (2%), Syncope (>1%), Upper abdominal pain (>1%), Vertigo (>1%) Frequency Not Defined Headache, Cough (rare) Potentially Fatal: Blood dyscrasias (e.g. neutropenia).

Valsartan, an angiotensin II type 1 (AT1) receptor antagonist, produces its BP lowering effects by inhibiting angiotensin II-induced vasoconstriction, aldosterone release and renal reabsorption of Na.

Tabuvan 1 160mg Tablets / Film-coated manufactured by Tabuk Pharmaceutical Manufacturing Co.. Its generic name is Valsartan. Tabuvan 1 is availble in United Arab Emirates. Farmaco UAE drug index information on Tabuvan 1 Tablets / Film-coated is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.